Medibiofarma

Medibiofarma is a private, clinical-stage biotech based in Madrid, Spain, advancing a pipeline of novel small molecules. Its lead asset, MBF-118, has completed a Phase 2a trial for fibrotic Crohn's disease, positioning the company as a development-stage entity. The firm employs a capital-efficient, virtual discovery model, concentrating internal expertise on drug design, chemistry, and IP while outsourcing later-stage preclinical work. Its strategy is to de-risk assets through clinical proof-of-concept before seeking licensing partnerships.

Target-based medicinal chemistry platform focused on designing first-in-class small molecules for clinically validated targets, with a specific focus on enabling T-cell infiltration in cancer.

In Crohn's disease, Medibiofarma competes with large biopharma companies and numerous biotechs developing anti-inflammatory and anti-fibrotic therapies. In immuno-oncology, the field is dominated by major players with significant resources, though niche approaches like enabling T-cell infiltration remain a active area of innovation with many competitors.